{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T06:16:56Z","timestamp":1772518616751,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ncl.2018.06.002","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T19:32:22Z","timestamp":1540323142000},"page":"739-750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Progressive Multifocal Leukoencephalopathy"],"prefix":"10.1016","volume":"36","author":[{"given":"Elena","family":"Grebenciucova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ncl.2018.06.002_bib1","first-page":"93","article-title":"Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease","volume":"81","author":"Astrom","year":"1958","journal-title":"Brain"},{"issue":"15","key":"10.1016\/j.ncl.2018.06.002_bib2","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1212\/WNL.0b013e3181f73600","article-title":"Incidence of progressive multifocal leukoencephalopathy in patients without HIV","volume":"75","author":"Amend","year":"2010","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ncl.2018.06.002_bib3","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.24966","article-title":"Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases","volume":"60","author":"Molloy","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ncl.2018.06.002_bib4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.msard.2017.01.006","article-title":"Classifying PML risk with disease modifying therapies","volume":"12","author":"Berger","year":"2017","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.ncl.2018.06.002_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ene.12304","article-title":"Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial","volume":"21","author":"Bozic","year":"2014","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2018.06.002_bib6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","article-title":"Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain","volume":"25","author":"Ferenczy","year":"2012","journal-title":"Clin Microbiol Rev"},{"issue":"21","key":"10.1016\/j.ncl.2018.06.002_bib7","doi-asserted-by":"crossref","first-page":"10290","DOI":"10.1128\/JVI.75.21.10290-10299.2001","article-title":"Potential transmission of human polyomaviruses through the gastrointestinal tract after exposure to virions or viral DNA","volume":"75","author":"Bofill-Mas","year":"2001","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.ncl.2018.06.002_bib8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamaneurol.2016.5537","article-title":"Distribution and quantity of sites of John Cunningham virus persistence in immunologically healthy patients: correlation with JC virus antibody and urine JC virus DNA","volume":"74","author":"Berger","year":"2017","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2018.06.002_bib9","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/jmv.20829","article-title":"Presence, quantitation and characterization of JC virus in the urine of Italian immunocompetent subjects","volume":"79","author":"Rossi","year":"2007","journal-title":"J\u00a0Med Virol"},{"issue":"1","key":"10.1016\/j.ncl.2018.06.002_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/13550289809113482","article-title":"Progressive multifocal leukoencephalopathy in patients with HIV infection","volume":"4","author":"Berger","year":"1998","journal-title":"J\u00a0Neurovirol"},{"key":"10.1016\/j.ncl.2018.06.002_bib11","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"},{"issue":"15","key":"10.1016\/j.ncl.2018.06.002_bib12","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.06.002_bib13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/1352458508096870","article-title":"Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA","volume":"15","author":"Iacobaeus","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.ncl.2018.06.002_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1148\/radiology.187.1.8451420","article-title":"Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation","volume":"187","author":"Whiteman","year":"1993","journal-title":"Radiology"},{"issue":"1\u20132","key":"10.1016\/j.ncl.2018.06.002_bib15","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jns.2014.06.018","article-title":"Low signal intensity in U-fiber identified by susceptibility-weighted imaging in two cases of progressive multifocal leukoencephalopathy","volume":"344","author":"Miyagawa","year":"2014","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.ncl.2018.06.002_bib16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0092-8674(90)90661-W","article-title":"VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4\/fibronectin binding site","volume":"60","author":"Elices","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.ncl.2018.06.002_bib17","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1172\/JCI117519","article-title":"The pathophysiologic role of \u03b14 integrins in\u00a0vivo","volume":"94","author":"Lobb","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ncl.2018.06.002_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jneuroim.2017.05.006","article-title":"CD4\/CD8 ratio during natalizumab treatment in multiple sclerosis patients","volume":"309","author":"Carotenuto","year":"2017","journal-title":"J\u00a0Neuroimmunol"},{"issue":"10","key":"10.1016\/j.ncl.2018.06.002_bib19","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.63.10.1383","article-title":"Altered CD4+\/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis","volume":"63","author":"St\u00fcve","year":"2006","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2018.06.002_bib20","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamaneurol.2014.63","article-title":"JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab","volume":"71","author":"Frohman","year":"2014","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2018.06.002_bib21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A\u00a0second-generation ELISA (STRATIFY JCV\u2122 DxSelect\u2122) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.ncl.2018.06.002_bib22","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s13365-016-0427-6","article-title":"Reassessing the risk of natalizumab-associated PML","volume":"22","author":"Berger","year":"2016","journal-title":"J\u00a0Neurovirol"},{"key":"10.1016\/j.ncl.2018.06.002_bib23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.msard.2016.03.005","article-title":"Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"8","author":"Borchardt","year":"2016","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.ncl.2018.06.002_bib24","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti\u2013JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.ncl.2018.06.002_bib25","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0000000000003739","article-title":"Challenges with incidence, resulting risk, and risk stratification","volume":"88","author":"Schwab","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ncl.2018.06.002_bib26","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2018.06.002_bib27","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1212\/WNL.0000000000002330","article-title":"Natalizumab-related PML 2\u00a0weeks after negative anti-JCV antibody assay","volume":"86","author":"Gagne Brosseau","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.06.002_bib28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.msard.2016.06.014","article-title":"Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: case report","volume":"9","author":"Miranda Acu\u00f1a","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ncl.2018.06.002_bib29","doi-asserted-by":"crossref","unstructured":"Schwanitz N, Boldt A, Stoppe M, et\u00a0al. Treatment, safety, and tolerance: longterm fingolimod treatment of multiple sclerosis induces phenotypical immunsenescence (P2.082). Neurology 2016;86(16 Supplement):P2.082.","DOI":"10.1212\/WNL.86.16_supplement.P2.082"},{"issue":"1","key":"10.1016\/j.ncl.2018.06.002_bib30","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1124\/jpet.111.190132","article-title":"Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway","volume":"341","author":"Scannevin","year":"2012","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.ncl.2018.06.002_bib31","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1212\/NXI.0000000000000340","article-title":"Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis","volume":"4","author":"Ghadiri","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ncl.2018.06.002_bib32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.msard.2015.05.003","article-title":"The effect of dimethyl fumarate (Tecfidera) on lymphocyte counts: a potential contributor to progressive multifocal leukoencephalopathy risk","volume":"4","author":"Khatri","year":"2015","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.ncl.2018.06.002_bib33","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/sj.jid.5700996","article-title":"Dimethyl fumarate reduces leukocyte rolling in\u00a0vivo through modulation of adhesion molecule expression","volume":"128","author":"Rubant","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"issue":"9","key":"10.1016\/j.ncl.2018.06.002_bib34","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A\u00a05-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2018.06.002_bib35","first-page":"696","article-title":"Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder","volume":"262","author":"Kim","year":"2015","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.ncl.2018.06.002_bib36","article-title":"PML Reported in patient receiving ocrelizumab","author":"Hughes","year":"2017","journal-title":"Medscape"},{"issue":"1","key":"10.1016\/j.ncl.2018.06.002_bib37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ana.24051","article-title":"Progressive multifocal leukoencephalopathy after natalizumab discontinuation","volume":"75","author":"Fine","year":"2014","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2018.06.002_bib38","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.ncl.2018.06.002_bib39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/504811","article-title":"Infectious complications associated with alemtuzumab use for lymphoproliferative disorders","volume":"43","author":"Martin","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ncl.2018.06.002_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-201781","article-title":"Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab","volume":"2014","author":"Isidoro","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.ncl.2018.06.002_bib41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1017\/S0317167100012105","article-title":"Monoclonal antibodies and progressive multifocal leukoencephalopathy","volume":"38","author":"Keene","year":"2011","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.ncl.2018.06.002_bib42","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1097\/TP.0b013e31818b62c8","article-title":"Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation","volume":"86","author":"Neff","year":"2008","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.ncl.2018.06.002_bib43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11910-017-0771-9","article-title":"Immunosenescence: the role of aging in the predisposition to neuro-infectious complications arising from the treatment of multiple sclerosis","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.ncl.2018.06.002_bib44","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.smim.2012.04.009","article-title":"Age-related changes in CD8 T\u00a0cell homeostasis and immunity to infection","volume":"24","author":"Nikolich-Zugich","year":"2012","journal-title":"Semin Immunol"},{"issue":"5","key":"10.1016\/j.ncl.2018.06.002_bib45","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s13365-017-0561-9","article-title":"Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy","volume":"23","author":"Prosperini","year":"2017","journal-title":"J\u00a0Neurovirol"},{"issue":"5","key":"10.1016\/j.ncl.2018.06.002_bib46","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ana.25070","article-title":"To do or not to do? Plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy","volume":"82","author":"Scarpazza","year":"2017","journal-title":"Ann Neurol"},{"issue":"19","key":"10.1016\/j.ncl.2018.06.002_bib47","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJM199805073381903","article-title":"Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team","volume":"338","author":"Hall","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ncl.2018.06.002_bib48","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.mehy.2005.01.037","article-title":"The atypical antipsychotic agents ziprasidone [correction of zisprasidone], risperdone and olanzapine as treatment for and prophylaxis against progressive multifocal leukoencephalopathy","volume":"65","author":"Altschuler","year":"2005","journal-title":"Med Hypotheses"},{"issue":"7","key":"10.1016\/j.ncl.2018.06.002_bib49","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3851\/IMP3032","article-title":"Clearance of cerebrospinal fluid JCV DNA with mirtazapine in a patient with progressive multifocal leukoencephalopathy and sarcoidosis","volume":"21","author":"Trentalange","year":"2016","journal-title":"Antivir Ther"},{"issue":"10","key":"10.1016\/j.ncl.2018.06.002_bib50","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40261-016-0433-8","article-title":"Treatment of Progressive Multifocal Leukoencephalopathy with Mirtazapine","volume":"36","author":"Jamilloux","year":"2016","journal-title":"Clin Drug Investig"},{"issue":"2","key":"10.1016\/j.ncl.2018.06.002_bib51","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/archneurol.2008.557","article-title":"Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy","volume":"66","author":"Cettomai","year":"2009","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2018.06.002_bib52","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s13365-013-0173-y","article-title":"A\u00a0study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes","volume":"19","author":"Clifford","year":"2013","journal-title":"J\u00a0Neurovirol"},{"issue":"2","key":"10.1016\/j.ncl.2018.06.002_bib53","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/S2352-3018(14)70027-X","article-title":"CADIRIS study team. Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial","volume":"1","author":"Sierra-Madero","year":"2014","journal-title":"Lancet HIV"},{"issue":"7","key":"10.1016\/j.ncl.2018.06.002_bib54","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1128\/JVI.75.7.3483-3487.2001","article-title":"JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy","volume":"75","author":"Koralnik","year":"2001","journal-title":"J\u00a0Virol"},{"issue":"11","key":"10.1016\/j.ncl.2018.06.002_bib55","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1212\/WNL.0b013e31822e55e7","article-title":"Immune reconstitution inflammatory syndrome in natalizumab-associated PML","volume":"77","author":"Tan","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.06.002_bib56","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1749-6632.2009.05111.x","article-title":"Neurological complications of immune reconstitution in HIV-infected populations","volume":"1184","author":"Johnson","year":"2010","journal-title":"Ann N Y Acad Sci"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861918312362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861918312362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:16:50Z","timestamp":1760005010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861918312362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0733861918312362"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2018.06.002","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progressive Multifocal Leukoencephalopathy","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2018.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}